Press releases
- Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
- Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
- Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
More ▼
Key statistics
On Friday, Akeso Inc (4RY:BER) closed at 5.20, -14.75% below its 52-week high of 6.10, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.10 |
---|---|
High | 5.30 |
Low | 5.10 |
Bid | 4.80 |
Offer | 5.75 |
Previous close | 3.88 |
Average volume | 110.00 |
---|---|
Shares outstanding | 865.86m |
Free float | 634.96m |
P/E (TTM) | 16.81 |
Market cap | 38.10bn HKD |
EPS (TTM) | 2.62 HKD |
Data delayed at least 15 minutes, as of May 31 2024 20:05 BST.
More ▼